Treatment efficacy and immune stimulation by adcd40l gene therapy of spontaneous canine malignant melanoma

Journal of Immunotherapy

Volumn 36, Issue 6, 2013, Pages 350-358

  Westberg, Sara ^a   Sadeghi, Arian ^b   Svensson, Emma ^b   Segall, Thomas ^c   Dimopoulou, Maria ^a   Korsgren, Olle ^b   Hemminki, Akseli ^d   Loskog, Angelica S I ^b   Tötterman, Thomas H ^b   Von Euler, Henrik ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adcd40l; Canine; Comparative oncology; Dogs; Immunotherapy; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CD40 LIGAND;

ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; B LYMPHOCYTE; CANCER GENE THERAPY; CLINICAL EFFECTIVENESS; CYTOREDUCTIVE SURGERY; DRUG FEVER; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IMMUNOTHERAPY; INJECTION SITE SWELLING; MALE; MELANOMA; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD40 LIGAND; CYTOKINES; DOGS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; NEOPLASM GRADING; NEOPLASM METASTASIS; PILOT PROJECTS;

EID: 84880208575     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31829d8a1b     Document Type: Article

References (50)

1. Cotchin E. Melanotic tumors of dogs. J Comp Pathol Ther. 1955;65:115-129.
2. Goldschmidt MH. Benign and malignant melanocytic neoplasms of domestic animals. Am J Dermatopathol. 1985; 7(suppl):203-212.
3. Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc. 1979;175:567-571.
4. Goldschmidt MH. Skin tumors of the dog and cat. In: Goldschmidt MH, Shofer FS, eds. Skin Tumors of the Dog and Cat. 1st ed. Tarrytown, NY: Pergamon Press; 1992:142-151.
5. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002;39:651-678.
6. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc. 1996;209:98-102.
7. Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J Vet Intern Med. 1999;13:163-174.
8. Mayr B, Schaffner G, Reifinger M, et al. N-ras mutations in canine malignant melanomas. Vet J. 2003;165:169-171.
9. Ross DA, Wilson GD. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. Br J Surg. 1997;84:803-807.
10. Guldberg P, Thor Straten P, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660-3663.
11. van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol. 1996;149:883-893.
12. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for malignant melanoma in dogs: results of randomized clinical trials using surgery, liposome encapsulated muramyl tripeptide, and granulocyte macrophage colony stimulating factor. Clin Cancer Res. 1999;5:4249-4258.
13. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003;9:1284-1290.
14. Knapp DW, Waters DJ. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today. 1997;3:8-11.
15. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990;9:125-136.
16. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000;18:781-792.
17. Ramos-Vara JA, Beissenherz ME, Miller MA, et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol. 2000;37:597-608.
18. Owen LN. TNM Classification of Tumours in Domestic Animals. 1st ed. Geneva: World Health Organization; 1980.
19. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol. 1979;16:32-40.
20. Harvey HJ, MacEwen EG, Braun D, et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc. 1981;178: 580-582.
21. MacEwen EG, Patnaik AK, Harvey HJ, et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 1986;4:397-402.
22. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091-3098.
23. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
24. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc. 2001;218: 1444-1448.
25. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
26. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27: 5763-5771.
27. Sun Y, Peng D, Lecanda J, et al. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther. 2000;7:1467-1476.
28. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10:1375-1387.
29. Loskog A, Ninalga C, Totterman TH. Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother. 2006;55:588-597.
30. Schonbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
31. Loskog AS, Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol. 2009;21:301-307.
32. Biagi E, Rousseau R, Yvon E, et al. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11:6916-6923.
33. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
34. Rousseau RF, Biagi E, Dutour A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006;107:1332-1341.
35. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
36. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280-3287.
37. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol. 2004;172:7200-7205.
38. Lindqvist C, Sandin LC, Fransson M, et al. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother. 2009;32:785-792.
39. Malmstrom PU, Loskog AS, Lindqvist CA, et al. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res. 2010;16:3279-3287.
40. von Euler H, Sadeghi A, Carlsson B, et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother. 2008;31:377-384.
41. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010;70:4297-4309.
42. Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v11. Vet Comp Oncol. 2011. [Epub ahead of print].
43. Scheibenbogen C, Mohler T, Haefele J, et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 1995;5:179-181.
44. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract. 2007;22:55-60.
45. Theon AP, Rodriguez C, Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J AmVetMed Assoc. 1997; 210:778-784.
46. Bolon B, Calderwood Mays MB, Hall BJ. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet Pathol. 1990;27:96-102.
47. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006;24:4582-4585.
48. Dow SW, Elmslie RE, Willson AP, et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998;101:2406-2414.
49. Thamm DH, Kurzman ID, Macewen EG, et al. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 2003;52:473-480.
50. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147-156.